Elevated angiography-derived microvascular resistance and HbA1c levels jointly predict adverse outcomes in patients with diabetic STEMI: a multicenter retrospective cohort study - Scorecard - MDSpire
Advertisement
Elevated angiography-derived microvascular resistance and HbA1c levels jointly predict adverse outcomes in patients with diabetic STEMI: a multicenter retrospective cohort study
Clinical Scorecard: Increased Microvascular Resistance from Angiography and HbA1c Levels as Predictors of Poor Outcomes in Diabetic STEMI Patients: A Multicenter Retrospective Analysis
At a Glance
Category
Detail
Condition
ST-segment elevation myocardial infarction (STEMI) in type 2 diabetes mellitus (T2DM)
Key Mechanisms
Angiography-derived microvascular resistance (AMR) and HbA1c levels
Target Population
Patients with new-onset STEMI and type 2 diabetes mellitus
Care Setting
Multicenter retrospective observational study
Key Highlights
Elevated AMR and HbA1c levels are independently associated with major adverse cardiovascular and cerebrovascular events (MACCEs).
Patients with HbA1c ≥6.5% and AMR ≥250.5 mmHg·s/m have the highest risk of MACCEs.
Nonlinear relationships exist between MACCEs and both HbA1c and AMR levels.
Combined evaluation of AMR and HbA1c enhances risk stratification for MACCEs.
Assessment of coronary microcirculatory function may improve long-term outcomes.
Guideline-Based Recommendations
Diagnosis
STEMI is defined by complete occlusion of a coronary artery due to thrombus formation over an atherosclerotic plaque.
Management
Patients must undergo percutaneous coronary intervention (PCI) for STEMI.
Monitoring & Follow-up
Monitor HbA1c levels and AMR post-PCI to assess risk for MACCEs.
Risks
Type 2 diabetes mellitus is a significant risk factor for adverse outcomes in STEMI patients.
Patient & Prescribing Data
Patients diagnosed with STEMI and type 2 diabetes mellitus.
Sustained optimization of glycemic control is important for improving clinical outcomes.
Clinical Best Practices
Incorporate AMR assessment in the evaluation of STEMI patients with diabetes.
Regularly monitor glycemic control in diabetic patients post-STEMI.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
